Loading…

Is there a place for magnesium in the treatment of acute myocardial infarction?

Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mort...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 1996-08, Vol.132 (2), p.471-477
Main Authors: Seelig, Mildred S., Elin, Ronald J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33
cites cdi_FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33
container_end_page 477
container_issue 2
container_start_page 471
container_title The American heart journal
container_volume 132
creator Seelig, Mildred S.
Elin, Ronald J.
description Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mortality rates with magnesium therapy in patients with acute myocardial infarction. In this article we explore the following four differences between the ISIS-4 study and the earlier studies: (1) Time of initiation of magnesium treatment after acute myocardial infarction and thrombolytic therapy; (2) dosage of magnesium in the first 24 hours after acute myocardial infarction; (3) duration of magnesium infusion after acute myocardial infarction; and (4) differences in patient risks in control and treatment groups. These four differences may explain the different outcomes among these studies and indicate the type of additional studies that are needed to define the clinical utility of magnesium infusion in the treatment of patients with acute myocardial infarction.
doi_str_mv 10.1016/S0002-8703(96)90338-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78199011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870396903385</els_id><sourcerecordid>78199011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMotVYfoZCFiC5Gk8lMJlkVKV4KhS7UdchkTjQyl5pkhL690wvdujoc_u9c-BCaUnJPCeUPb4SQNBEFYbeS30nCmEjyEzSmRBYJL7LsFI2PyDm6COF7aHkq-AiNBJfZ0IzRahFw_AIPWON1rQ1g23nc6M8Wgusb7NptjKMHHRtoI-4s1qaPgJtNZ7SvnK4HyGpvouva2SU6s7oOcHWoE_Tx_PQ-f02Wq5fF_HGZGCZkTAQQUUKZCyk4IzbNU0EyloKu0pRLxigtrSlTzkrCSjA8p1QKSwtaSiayirEJutnvXfvup4cQVeOCgbrWLXR9UIWgUhJKBzDfg8Z3IXiwau1do_1GUaK2ItVOpNpaUpKrnUiVD3PTw4G-bKA6Th3MDfn1IdfB6Np63RoXjhijIs9EMWCzPQaDjF8HXgXjoDVQOQ8mqqpz_zzyB394jdY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78199011</pqid></control><display><type>article</type><title>Is there a place for magnesium in the treatment of acute myocardial infarction?</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Seelig, Mildred S. ; Elin, Ronald J.</creator><creatorcontrib>Seelig, Mildred S. ; Elin, Ronald J.</creatorcontrib><description>Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mortality rates with magnesium therapy in patients with acute myocardial infarction. In this article we explore the following four differences between the ISIS-4 study and the earlier studies: (1) Time of initiation of magnesium treatment after acute myocardial infarction and thrombolytic therapy; (2) dosage of magnesium in the first 24 hours after acute myocardial infarction; (3) duration of magnesium infusion after acute myocardial infarction; and (4) differences in patient risks in control and treatment groups. These four differences may explain the different outcomes among these studies and indicate the type of additional studies that are needed to define the clinical utility of magnesium infusion in the treatment of patients with acute myocardial infarction.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/S0002-8703(96)90338-5</identifier><identifier>PMID: 8694006</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Biological and medical sciences ; Calcium Channel Blockers - therapeutic use ; Cardiovascular system ; Clinical Trials as Topic ; Humans ; Infusions, Intravenous ; Magnesium Sulfate - therapeutic use ; Medical sciences ; Miscellaneous ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Myocardial Reperfusion ; Pharmacology. Drug treatments ; Thrombolytic Therapy ; Treatment Outcome</subject><ispartof>The American heart journal, 1996-08, Vol.132 (2), p.471-477</ispartof><rights>1996</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33</citedby><cites>FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3185487$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8694006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seelig, Mildred S.</creatorcontrib><creatorcontrib>Elin, Ronald J.</creatorcontrib><title>Is there a place for magnesium in the treatment of acute myocardial infarction?</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mortality rates with magnesium therapy in patients with acute myocardial infarction. In this article we explore the following four differences between the ISIS-4 study and the earlier studies: (1) Time of initiation of magnesium treatment after acute myocardial infarction and thrombolytic therapy; (2) dosage of magnesium in the first 24 hours after acute myocardial infarction; (3) duration of magnesium infusion after acute myocardial infarction; and (4) differences in patient risks in control and treatment groups. These four differences may explain the different outcomes among these studies and indicate the type of additional studies that are needed to define the clinical utility of magnesium infusion in the treatment of patients with acute myocardial infarction.</description><subject>Biological and medical sciences</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cardiovascular system</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Magnesium Sulfate - therapeutic use</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Reperfusion</subject><subject>Pharmacology. Drug treatments</subject><subject>Thrombolytic Therapy</subject><subject>Treatment Outcome</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKAzEUhoMotVYfoZCFiC5Gk8lMJlkVKV4KhS7UdchkTjQyl5pkhL690wvdujoc_u9c-BCaUnJPCeUPb4SQNBEFYbeS30nCmEjyEzSmRBYJL7LsFI2PyDm6COF7aHkq-AiNBJfZ0IzRahFw_AIPWON1rQ1g23nc6M8Wgusb7NptjKMHHRtoI-4s1qaPgJtNZ7SvnK4HyGpvouva2SU6s7oOcHWoE_Tx_PQ-f02Wq5fF_HGZGCZkTAQQUUKZCyk4IzbNU0EyloKu0pRLxigtrSlTzkrCSjA8p1QKSwtaSiayirEJutnvXfvup4cQVeOCgbrWLXR9UIWgUhJKBzDfg8Z3IXiwau1do_1GUaK2ItVOpNpaUpKrnUiVD3PTw4G-bKA6Th3MDfn1IdfB6Np63RoXjhijIs9EMWCzPQaDjF8HXgXjoDVQOQ8mqqpz_zzyB394jdY</recordid><startdate>19960801</startdate><enddate>19960801</enddate><creator>Seelig, Mildred S.</creator><creator>Elin, Ronald J.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960801</creationdate><title>Is there a place for magnesium in the treatment of acute myocardial infarction?</title><author>Seelig, Mildred S. ; Elin, Ronald J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Biological and medical sciences</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cardiovascular system</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Magnesium Sulfate - therapeutic use</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Reperfusion</topic><topic>Pharmacology. Drug treatments</topic><topic>Thrombolytic Therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seelig, Mildred S.</creatorcontrib><creatorcontrib>Elin, Ronald J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seelig, Mildred S.</au><au>Elin, Ronald J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is there a place for magnesium in the treatment of acute myocardial infarction?</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>1996-08-01</date><risdate>1996</risdate><volume>132</volume><issue>2</issue><spage>471</spage><epage>477</epage><pages>471-477</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mortality rates with magnesium therapy in patients with acute myocardial infarction. In this article we explore the following four differences between the ISIS-4 study and the earlier studies: (1) Time of initiation of magnesium treatment after acute myocardial infarction and thrombolytic therapy; (2) dosage of magnesium in the first 24 hours after acute myocardial infarction; (3) duration of magnesium infusion after acute myocardial infarction; and (4) differences in patient risks in control and treatment groups. These four differences may explain the different outcomes among these studies and indicate the type of additional studies that are needed to define the clinical utility of magnesium infusion in the treatment of patients with acute myocardial infarction.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>8694006</pmid><doi>10.1016/S0002-8703(96)90338-5</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-8703
ispartof The American heart journal, 1996-08, Vol.132 (2), p.471-477
issn 0002-8703
1097-6744
language eng
recordid cdi_proquest_miscellaneous_78199011
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
subjects Biological and medical sciences
Calcium Channel Blockers - therapeutic use
Cardiovascular system
Clinical Trials as Topic
Humans
Infusions, Intravenous
Magnesium Sulfate - therapeutic use
Medical sciences
Miscellaneous
Myocardial Infarction - drug therapy
Myocardial Infarction - mortality
Myocardial Reperfusion
Pharmacology. Drug treatments
Thrombolytic Therapy
Treatment Outcome
title Is there a place for magnesium in the treatment of acute myocardial infarction?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T11%3A19%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20there%20a%20place%20for%20magnesium%20in%20the%20treatment%20of%20acute%20myocardial%20infarction?&rft.jtitle=The%20American%20heart%20journal&rft.au=Seelig,%20Mildred%20S.&rft.date=1996-08-01&rft.volume=132&rft.issue=2&rft.spage=471&rft.epage=477&rft.pages=471-477&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/S0002-8703(96)90338-5&rft_dat=%3Cproquest_cross%3E78199011%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78199011&rft_id=info:pmid/8694006&rfr_iscdi=true